MedPath

A phase II study with oxaliplatin, 5FU, Cetuximab and radiotherapy for treatment of non-resectable, locally advanced tu not metastatic cancer of oersophagus or the cardia regio

Conditions
Patients with histologically verified inoperable, locally advanced but non metastastic oesophageal ca or the ca of cardia region
Registration Number
EUCTR2008-006802-40-NO
Lead Sponsor
Akademiska University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
90
Inclusion Criteria

•Histologically verified squamous cell carcinoma or adenocarcinoma of the oesophagus or cardia (Siewert I-II)
•Performance status (WHO) 0-2, age 18-80 y
•Locally advanced disease non-resectable (T4 N0-N3, M0) or disease which is not operable for any other reason (T2/T3 N0-N3, M0)
•Adequate hematological, liver and renal function
•Written informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Distant metastases
•Prior chemotherapy or radiotherapy for oesophageal ca or ca of the cardia region
•Symptomatic peripheral neuropathy equal to or greater than NCI grade 2
•Other concomitant serious illness or medical condition that would not permit the patient to complete the study treatment or sign the informed concent
•Myocardial infarction within 6 months prior to study entry
•Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) unless treated, in remission and off active treatment for greater than 5 years
•Pregnancy

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath